Current Report Filing (8-k)
April 07 2021 - 9:33AM
Edgar (US Regulatory)
0001083446
false
0001083446
2021-04-07
2021-04-07
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): April 7, 2021
APOLLO MEDICAL HOLDINGS, INC.
(Exact name of registrant as specified
in its charter)
Delaware
|
|
001-37392
|
|
95-4472349
|
(State or Other
Jurisdiction
|
|
(Commission File
|
|
(I.R.S. Employer
|
of Incorporation)
|
|
Number)
|
|
Identification
Number)
|
1668 S. Garfield Avenue, 2nd Floor, Alhambra,
CA 91801
(Address of Principal Executive Offices,
and Zip Code)
(626) 282-0288
Registrant’s Telephone Number,
Including Area Code
(Former Name or Former Address, if Changed
Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Precommencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Precommencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange
Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock
|
AMEH
|
Nasdaq Capital Market
|
|
Item 7.01
|
Regulation FD Disclosure.
|
Apollo Medical Holdings, Inc. (the “Company”)
will conduct meetings with members of the investment community in April 2021
as a part of a non-deal roadshow, and has prepared presentation materials that the Company intends to use in this regard. A copy of the
presentation materials to be used is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information contained
in this Current Report on Form 8-K, including the exhibit referenced herein, is being furnished and shall not be deemed “filed”
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to
the liabilities of that section. Such information shall not be incorporated by reference into any filing under the Securities Act of 1933,
as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such
filing. The furnishing of this information will not be deemed an admission as to the materiality of any information contained herein.
|
Item 9.01
|
Financial Statements and Exhibits
|
(d) Exhibits.
Forward-Looking Statements
This current report on
Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended. These statements include words such as “forecast,” “guidance,”
“projects,” “estimates,” “anticipates,” “believes,” “expects,” “intends,”
“may,” “plans,” “seeks,” “should,” or “will,” or the negative of these words
or similar words. Forward-looking statements involve certain risks and uncertainties, and actual results may differ materially from those
discussed in each such statement. A number of important factors could cause actual results to differ materially from those included within
or contemplated by the forward-looking statements, including, but not limited to, the factors described in our filings with the Securities
and Exchange Commission, including the Company’s most recent annual report on Form 10-K and any subsequent quarterly reports on
Form 10-Q. The Company does not undertake any responsibility to update any of these factors or to announce publicly any revisions to any
of the forward-looking statements contained in this or any other document, whether as a result of new information, future events, or otherwise.
SIGNATURES
Pursuant to the requirements of the Securities
and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
APOLLO MEDICAL HOLDINGS, INC.
|
|
|
|
|
Dated: April 7, 2021
|
By:
|
/s/ Thomas S. Lam
|
|
Name:
|
Thomas S. Lam, M.D., M.P.H.
|
|
Title:
|
Co - Chief Executive Officer & President
|
Apollo Medical (NASDAQ:AMEH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Apollo Medical (NASDAQ:AMEH)
Historical Stock Chart
From Apr 2023 to Apr 2024